CureVac N.V. (LON: 0A9E)
London
· Delayed Price · Currency is GBP · Price in USD
3.940
-0.199 (-4.80%)
At close: Jan 22, 2025
CureVac Revenue
CureVac had revenue of 14.44M EUR in the quarter ending June 30, 2024, with 90.47% growth. This brings the company's revenue in the last twelve months to 65.86M, up 75.12% year-over-year. In the year 2023, CureVac had annual revenue of 53.76M, down -20.26%.
Revenue (ttm)
65.86M EUR
Revenue Growth
+75.12%
P/S Ratio
n/a
Revenue / Employee
56.19K EUR
Employees
1,172
Market Cap
721.24M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Shell | 221.41B |
AstraZeneca | 38.20B |
HSBC Holdings | 43.25B |
Unilever | 51.12B |
Rio Tinto Group | 42.87B |
RELX PLC | 9.30B |
BP p.l.c. | 144.69B |
British American Tobacco p.l.c. | 26.18B |
CureVac News
- 12 days ago - Why CureVac (CVAC) Shares Are Volatile - Benzinga
- 14 days ago - CureVac: Latest GBM Data Bodes Well For Next Program Check Point - Seeking Alpha
- 14 days ago - Why CureVac (CVAC) Stock Is Moving - Benzinga
- 15 days ago - Vaccine makers’ shares jump after bird flu death in US - Financial Times
- 2 months ago - CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update - Accesswire
- 2 months ago - CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - Accesswire
- 2 months ago - CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer - Accesswire